Cardiology

In this video, Michael J. Bloch, MD, discusses the use of combined oral contraceptives, which are the most common forms of birth control used by women in the United States, oral estrogen-free progestin-only...

In this video, Michael J. Bloch, MD, discusses any cardiovascular benefits to the use of estrogen-free oral contraceptives in women, including a recently published study on the association of menstrual...

In this video, Matthew C. Tattersall, DO, MS, provides an overview of the results from the study “Skeletal Muscle Adiposity and Lung Function Trajectory in the Severe Asthma Research Program,” including the...

In this podcast, Dr Harrison and Paul Shiu, DO, discuss hypertension urgency and emergency, what happens if hypertension is not properly managed, managing hypertension in the elderly, and in women who are...

In this article, Michael J. Bloch, MD, writes about orthostatic hypotension (OH), which is a frequent problem in patients with hypertension, including the approach to diagnosis and management of patients...

In this video, Michael J. Bloch, MD, discusses the implications of a recently published study on the association of menstrual cycle regularity and length with cardiovascular diseases, including gaps in the...

In this commentary, Michael J Bloch, MD, writes about the use of acetaminophen for pain control in patients with hypertension and patients with an increased risk of cardiovascular events, including results...

In this podcast episode, Dr Seth Martin interviews Jessica Golbus, MD, about the Science Advisory Group from the American Heart Association on digital technology in cardiac rehabilitation, including the...

In this video, Michael J. Bloch, MD, reviews and discusses a recently published study on the association of menstrual cycle regularity and length with cardiovascular diseases, including how the results...

In this video, Zeenat Safdar, MD, MS, a STELLAR trial investigator, discusses the STELLAR trial results, which supported the FDA approval of sotatercept. Sotatercept is the first activin signaling inhibitor...